Direct-Acting Antiviral Medicines Market Analysis

The market is segmented based on drug class into NS3/4A protease inhibitors, NS5A polymerase inhibitors, NS5B polymerase inhibitors, and combination drugs, out of which, the combination drugs segment is anticipated to grab the largest share by the end of 2021 on account of being evaluated as suitable medicine for treatment of liver diseases in a large number of clinical trials. Moreover, there is a significant growth in investment on these trials, which is also projected to contribute to the growth of the segment during the forecast period.

On the basis of end-user, the hospital pharmacies segment in the direct-acting antiviral medicines market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that more patients choose hospitals as their treatment option and there is an increased availability of prescribed antiviral medicines at hospital pharmacies.

Our in-depth analysis of the global market includes the following segments

By Drug Class Type	NS3/4A protease inhibitors NS5A Polymerase Inhibitors NS5B Polymerase Inhibitors Combination Drugs
By End-User	Hospital Pharmacies Retail Pharmacies Others

Frequently Asked Questions (FAQ)

Increasing prevalence of liver cirrhosis and hepatocellular carcinoma and the growing investment in the development of advanced therapies are the key factors driving market growth.

The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2021-2029.

Low access to direct-acting antiviral medicines in low economic regions and side effects of direct-acting antiviral medicines are estimated to hamper market growth.

The market in Asia Pacific region will provide ample growth opportunities owing to the increasing hepatitis C infection prevalence and rising focus of major companies for expanding their product to countries in the region.

The major players dominating the direct-acting antiviral medicines market are AbbVie, Inc., Janssen Therapeutics, Bristol-Myers Squibb, and Merck & Co. among others.

Direct-Acting Antiviral Medicines Market Analysis